Published in Women's Health Weekly, May 1st, 2006
Scientists in Indonesia conducted a study "to investigate the effect of vitamin K2 (menatetrenone) treatment on bone mineral density (BMD) and a bone metabolic marker (osteocalcin) in postmenopausal women with osteoporosis living in Indonesia." They performed "a double-blind randomized placebo-controlled study of 63 postmenopausal women with osteoporosis."
"The vitamin K2 group (n=33) received 45 mg menatetrenone and 1500 mg calcium carbonate per day and the control group (n=30) received placebo and 1500 mg calcium carbonate per...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.